Mesguich C - Search Results

1

Prognostic utility of pre-transplantation [¹⁸ F] fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma who underwent rituximab, dexamethasone, high-dose cytarabine, carboplatin salvage chemotherapy.

Mesguich C, Roch A, Hindié E, Milpied N, Bordenave L, Tlili G, Bouabdallah K. Mesguich C, et al. Br J Haematol. 2020 Jan;188(2):268-271. doi: 10.1111/bjh.16144. Epub 2019 Aug 6. Br J Haematol. 2020. PMID: 31388998 Free article.

2

Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.

Mesguich C, Cazeau AL, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, Bordenave L, Hindié E. Mesguich C, et al. Br J Haematol. 2016 Nov;175(4):652-660. doi: 10.1111/bjh.14292. Epub 2016 Aug 19. Br J Haematol. 2016. PMID: 27539369 Free article.

3

Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.

Mesguich C, Cazeau AL, Bouabdallah K, Hindié E. Mesguich C, et al. Br J Haematol. 2018 Apr;181(1):124-125. doi: 10.1111/bjh.14494. Epub 2017 Jan 20. Br J Haematol. 2018. PMID: 28106255 Free article. No abstract available.

4

Additional Evidence That End-of-Treatment Fluorodeoxyglucose-Positron Emission Tomography Evaluation Is Necessary in Advanced Hodgkin Lymphoma.

Mesguich C, Bouabdallah K, Milpied N, Hindié E. Mesguich C, et al. J Clin Oncol. 2018 Jul 10;36(20):2124-2125. doi: 10.1200/JCO.2018.78.6780. Epub 2018 May 23. J Clin Oncol. 2018. PMID: 29791291 No abstract available.

5

New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma.

Mesguich C, Zanotti-Fregonara P, Hindié E. Mesguich C, et al. Theranostics. 2016 Jan 1;6(2):287-90. doi: 10.7150/thno.14400. eCollection 2016. Theranostics. 2016. PMID: 26877786 Free PMC article.

6

Choline PET/CT in Multiple Myeloma.

Mesguich C, Hulin C, Lascaux A, Bordenave L, Marit G, Hindié E. Mesguich C, et al. Cancers (Basel). 2020 May 28;12(6):1394. doi: 10.3390/cancers12061394. Cancers (Basel). 2020. PMID: 32481661 Free PMC article. Review.

7

Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial.

Mesguich C, Hulin C, Latrabe V, Asselineau J, Bordenave L, Perez P, Hindie E, Marit G. Mesguich C, et al. JMIR Res Protoc. 2020 Sep 10;9(9):e17850. doi: 10.2196/17850. JMIR Res Protoc. 2020. PMID: 32909953 Free PMC article.

8

Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.

Mesguich C, Hulin C, Latrabe V, Lascaux A, Bordenave L, Hindié E, Marit G. Mesguich C, et al. Ann Hematol. 2020 Dec;99(12):2869-2880. doi: 10.1007/s00277-020-04265-2. Epub 2020 Sep 19. Ann Hematol. 2020. PMID: 32951093

9

Prospective Comparison of 18-FDG PET/CT and Whole-Body MRI with Diffusion-Weighted Imaging in the Evaluation of Treatment Response of Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant.

Mesguich C, Latrabe V, Hulin C, Lascaux A, Bordenave L, Hindié E, Marit G. Mesguich C, et al. Cancers (Basel). 2021 Apr 16;13(8):1938. doi: 10.3390/cancers13081938. Cancers (Basel). 2021. PMID: 33923781 Free PMC article.

10

Role of ¹⁸F-FDG PET/CT in Posttreatment Evaluation of Anal Carcinoma.

Houard C, Pinaquy JB, Mesguich C, Henriques de Figueiredo B, Cazeau AL, Allard JB, Laharie H, Bordenave L, Fernandez P, Vendrely V. Houard C, et al. Among authors: mesguich c. J Nucl Med. 2017 Sep;58(9):1414-1420. doi: 10.2967/jnumed.116.185280. Epub 2017 Mar 9. J Nucl Med. 2017. PMID: 28280225 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

26 results

Search Page